NCT00797862
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
See it on ClinicalTrials.gov ↗1,254 people
49.4%
50.6%
619 womenmiddle line = equal numbers635 men
- Phase
- PHASE3
- Paid for by
- Novartis
- Finished
- 2010-11
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 58.1 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or nursing (lactating) women”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or nursing (lactating) women”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Pre-menopausal women not taking accepted form of birth control”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of cardiovascular conditions”
- No diabetes
Women with diabetes were turned away.
“Uncontrolled Type 1 or Type 2 diabetes mellitus”
Study titles and rules are shown in their original English.